In autoimmune diseases, dysregulated ILC activity is increasingly recognized as a contributor to chronic inflammation and tissue damage; elevated ILC1 and ILC3 populations have been implicated in conditions such as systemic lupus erythematosus and rheumatoid arthritis (38, 39). This evidence concerns the gene CCL27 and systemic lupus erythematosus.